No­vo Nordisk looks in­to start­ing GLP-1 drug tri­als for ad­dic­tion

No­vo Nordisk is con­sid­er­ing in­ves­ti­gat­ing its GLP-1 ther­a­pies in the treat­ment of ad­dic­tions, mir­ror­ing sim­i­lar com­ments made by its ma­jor in­cretin ri­val Eli Lil­ly. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER